# A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia

> **NCT04471064** · PHASE1 · UNKNOWN · sponsor: **Shijiazhuang Yiling Pharmaceutical Co. Ltd** · enrollment: 60 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** XY0206

## Key facts

- **NCT ID:** NCT04471064
- **Lead sponsor:** Shijiazhuang Yiling Pharmaceutical Co. Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-15
- **Primary completion:** 2024-02
- **Final completion:** 2024-02
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04471064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04471064, "A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04471064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*